Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

In silico Study of Alkaloid Compounds with Computational Approach for Selection of Drug Leads for COVID-19

Author(s): Stephanie Audrey Victoria, Ihsan Tria Pramanda and Arli Aditya Parikesit*

Volume 4, Issue 3, 2023

Published on: 23 August, 2023

Article ID: e230823220280 Pages: 11

DOI: 10.2174/2666796704666230823164137

Price: $65

Abstract

Background: The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virulent source of COVID-19 disease. As a result of the rapid transmission of the viral agent and deficiency of specific drugs against the virus, a worldwide pandemic ensued with a terrifying death toll. Thus there is tremendous urgency to discover substances for the development of specific COVID-19 drugs. With increasing public interest in natural products, this study aims to discover alkaloid compounds capable of inhibiting SARS-CoV-2 with the assistance of bioinformatics.

Methods: In this work, 298 alkaloids with reported antiviral properties were identified, and their biological activities were validated with QSAR analysis using the Pass Online server until only 7 alkaloids remained. Molecular docking studies for these 7 alkaloids onto SARS-CoV-2 3CLpro, a protein involved in viral replication, were carried out with AutoDock Vina, followed by in silico visualization of the proteinalkaloid interaction with Ligplot+ program and prediction of ADME-Tox properties of the alkaloids using Toxtree program and SwissADME online server.

Results: Fangchinoline, phenanthroindolizidine, and polyalthenol are predicted to have strong binding affinity with SARS-CoV-2 3CLpro. Visualization of the molecular interactions between the ligand and protein target, however, showed that homonojirimycin formed the most hydrogen bonds with the protein binding site. Most of the alkaloids have little to no violation of Lipinski’s Rule of 5, easy to moderate synthetic accessibility, and good pharmacokinetic properties.

Conclusion: Fangchinoline, phenanthroindolizidine, and polyalthenol exhibited high binding affinity values to SARS-CoV-2 3CLpro, with polyalthenol predicted to possess the strongest binding interactions to the active site of the protein. Polyalthenol and phenanthroindolizidine confer the most versatility in terms of bioavailability, however, supplementary observation of phenanthroindolizidine for the prospect of mutagenicity is required before it can be recommended for further drug development.

Graphical Abstract

[1]
Pal M, Berhanu G, Desalegn C, Kandi V. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): An update. Cureus 2020; 12(3): e7423.
[http://dx.doi.org/10.7759/cureus.7423] [PMID: 32337143]
[2]
World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Available from:https://covid19.who.int/ (Accessed August 26, 2021)
[3]
Chakraborty R, Parvez S. COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials. Biochem Pharmacol 2020; 180: 114184.
[http://dx.doi.org/10.1016/j.bcp.2020.114184] [PMID: 32739342]
[4]
Cao X. COVID-19: Immunopathology and its implications for therapy. Nat Rev Immunol 2020; 20(5): 269-70.
[http://dx.doi.org/10.1038/s41577-020-0308-3] [PMID: 32273594]
[5]
Lotfi M, Hamblin MR, Rezaei N. COVID-19: Transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta 2020; 508: 254-66.
[http://dx.doi.org/10.1016/j.cca.2020.05.044] [PMID: 32474009]
[6]
Antonio AS, Wiedemann LSM, Veiga-Junior VF. Natural products’ role against COVID-19. RSC Advances 2020; 10(39): 23379-93.
[http://dx.doi.org/10.1039/D0RA03774E] [PMID: 35693131]
[7]
Cushnie TPT, Cushnie B, Lamb AJ. Alkaloids: An overview of their antibacterial, antibiotic-enhancing and antivirulence activities. Int J Antimicrob Agents 2014; 44(5): 377-86.
[http://dx.doi.org/10.1016/j.ijantimicag.2014.06.001] [PMID: 25130096]
[8]
Nagasathiya Krishnan , Velmurugan Devadasan , Pachaiappan Raman . Plant-derived alkaloids as anti-viral agents. Int J Res Pharmaceut Sci 2020; 11(4): 6174-82.
[http://dx.doi.org/10.26452/ijrps.v11i4.3291]
[9]
Boozari M, Hosseinzadeh H. Natural products for COVID ‐19 prevention and treatment regarding to previous coronavirus infections and novel studies. Phytother Res 2021; 35(2): 864-76.
[http://dx.doi.org/10.1002/ptr.6873] [PMID: 32985017]
[10]
Adisurja GP, Parikesit AA. Virtual screening of the flavonoids compounds with the SARS-CoV-2 3C-like protease as the lead compounds for the COVID-19. Coronaviruses 2021; 2(11): 1-9.
[http://dx.doi.org/10.2174/2666796702666210222105547]
[11]
Parikesit AA, Nurdiansyah R. The predicted structure for the Anti-Sense siRNA of the RNA polymerase Enzyme (RdRp) gene of the SARS-CoV-2. Berita Biologi 2020; 19(1): 97-108.
[http://dx.doi.org/10.14203/beritabiologi.v19i1.3849]
[12]
Malau ND, Azzahra SF. Molecular Docking Studies of Potential Quercetin 3,4′-dimethyl ether 7-alpha-LArabinofuranosyl-(1-6)-glucoside as Inhibitor antimalaria. J Phys Conf Ser 2020; 1428(1): 012057.
[http://dx.doi.org/10.1088/1742-6596/1428/1/012057]
[13]
Ursu O, Rayan A, Goldblum A, Oprea TI. Understanding druglikeness. Wiley Interdiscip Rev Comput Mol Sci 2011; 1(5): 760-81.
[http://dx.doi.org/10.1002/wcms.52]
[14]
Ertl P, Schuffenhauer A. Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions. J Cheminform 2009; 1(1): 8.
[http://dx.doi.org/10.1186/1758-2946-1-8] [PMID: 20298526]
[15]
Trypsteen W, Van Cleemput J, Snippenberg W, Gerlo S, Vandekerckhove L. On the whereabouts of SARS-CoV-2 in the human body: A systematic review. PLoS Pathog 2020; 16(10): e1009037.
[http://dx.doi.org/10.1371/journal.ppat.1009037] [PMID: 33125439]
[16]
Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017; 7(1): 42717.
[http://dx.doi.org/10.1038/srep42717] [PMID: 28256516]
[17]
Mudide A, Alterovitz G. SARS-CoV-2 drug discovery based on intrinsically disordered regions. Pac Symp Biocomput 2020; 26(26): 131-42.
[http://dx.doi.org/10.1142/9789811232701_0013] [PMID: 33691011]
[18]
Afriza D, Suriyah WH, Ichwan SJA. In silico analysis of molecular interactions between the anti-apoptotic protein survivin and dentatin, nordentatin, and quercetin. J Phys Conf Ser 2018; 1073(3): 032001.
[http://dx.doi.org/10.1088/1742-6596/1073/3/032001]
[19]
Yang CW, Lee YZ, Kang IJ, et al. Identification of phenanthroindolizines and phenanthroquinolizidines as novel potent anti-coronaviral agents for porcine enteropathogenic coronavirus transmissible gastroenteritis virus and human severe acute respiratory syndrome coronavirus. Antiviral Res 2010; 88(2): 160-8.
[http://dx.doi.org/10.1016/j.antiviral.2010.08.009] [PMID: 20727913]
[20]
Jia X, Zhao H, Du C, Tang W, Wang X. Possible pharmaceutical applications can be developed from naturally occurring phenanthroindolizidine and phenanthroquinolizidine alkaloids. Phytochem Rev 2021; 20(4): 845-68.
[http://dx.doi.org/10.1007/s11101-020-09723-3] [PMID: 32994757]
[21]
Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798): 270-3.
[http://dx.doi.org/10.1038/s41586-020-2012-7] [PMID: 32015507]
[22]
Kim D, Min J, Jang M, et al. Natural bis-benzylisoquinoline alkaloids-tetrandrine, fangchinoline, and cepharanthine, inhibit human coronavirus OC43 infection of MRC-5 human lung cells. Biomolecules 2019; 9(11): 696.
[http://dx.doi.org/10.3390/biom9110696] [PMID: 31690059]
[23]
Fielding BC, da Silva Maia Bezerra Filho C, Ismail NSM, Sousa DP. Alkaloids: Therapeutic potential against human coronaviruses. Molecules 2020; 25(23): 5496.
[http://dx.doi.org/10.3390/molecules25235496] [PMID: 33255253]
[24]
Uzor PF. Alkaloids from plants with antimalarial activity: A review of recent studies. Evid Based Complement Alternat Med 2020; 2020: 1-17.
[http://dx.doi.org/10.1155/2020/8749083] [PMID: 32104196]
[25]
Tajuddeen N, Van Heerden FR. Antiplasmodial natural products: An update. Malar J 2019; 18(1): 404.
[http://dx.doi.org/10.1186/s12936-019-3026-1] [PMID: 31805944]
[26]
Rai H, Barik A, Singh YP, et al. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: An effort toward drug repurposing to combat COVID-19. Mol Divers 2021; 25(3): 1905-27.
[http://dx.doi.org/10.1007/s11030-021-10188-5] [PMID: 33582935]
[27]
Inam A, Van Zyl RL, van Vuuren NJ, et al. Chloroquinoline–acetamide hybrids: A promising series of potential antiprotozoal agents. RSC Advances 2015; 5(60): 48368-81.
[http://dx.doi.org/10.1039/C5RA05472A]
[28]
Ferreira de Freitas R, Schapira M. A systematic analysis of atomic protein-ligand interactions in the PDB. MedChemComm 2017; 8(10): 1970-81.
[http://dx.doi.org/10.1039/C7MD00381A] [PMID: 29308120]
[29]
Klebe G. Protein-ligand interactions as the basis for drug action. In: Drug Design. Berlin, Heidelberg: Springer 2013; pp. 61-88.
[http://dx.doi.org/10.1007/978-3-642-17907-5_4]
[30]
Schmidtke P. Protein-ligand binding sites. Identification, characterization and interrelations. PhD thesis, Universitat de Barcelona: Barcelona, October 2011
[31]
Betz M, Wulsdorf T, Krimmer SG, Klebe G. Impact of surface water layers on protein-ligand binding: How well are experimental data reproduced by molecular dynamics simulations in a thermolysin test case? J Chem Inf Model 2016; 56(1): 223-33.
[http://dx.doi.org/10.1021/acs.jcim.5b00621] [PMID: 26691064]
[32]
Chen D, Oezguen N, Urvil P, Ferguson C, Dann SM, Savidge TC. Regulation of protein-ligand binding affinity by hydrogen bond pairing. Sci Adv 2016; 2(3): e1501240.
[http://dx.doi.org/10.1126/sciadv.1501240] [PMID: 27051863]
[33]
Germain M, Meyre ME, Poul L, et al. Priming the body to receive the therapeutic agent to redefine treatment benefit/risk profile. Sci Rep 2018; 8(1): 4797.
[http://dx.doi.org/10.1038/s41598-018-23140-9] [PMID: 29556068]
[34]
Carozzi V, Cavaletti G. Toxicities of therapeutic agents used in medicine. Toxics 2016; 4(3): 14.
[http://dx.doi.org/10.3390/toxics4030014] [PMID: 29051418]
[35]
Dhoble S, Dhage S, Pulakkat S, Patravale VB. Opportunities and challenges in targeted carrier-based intracellular drug delivery: Increased efficacy and reduced toxicity. In: Novel Drug Delivery Technologies. Singapore: Springer 2019; pp. 403-31.
[http://dx.doi.org/10.1007/978-981-13-3642-3_12]
[36]
Seth R, Kydd ASR, Buchbinder R, Bombardier C, Edwards CJ. Allopurinol for chronic gout. Cochrane Libr 2014; 2014(12): CD006077.
[http://dx.doi.org/10.1002/14651858.CD006077.pub3] [PMID: 25314636]
[37]
Quimque MTJ, Notarte KIR, Fernandez RAT, et al. Virtual screening-driven drug discovery of SARS-CoV2 enzyme inhibitors targeting viral attachment, replication, post-translational modification and host immunity evasion infection mechanisms. J Biomol Struct Dyn 2021; 39(12): 4316-33.
[http://dx.doi.org/10.1080/07391102.2020.1776639] [PMID: 32476574]
[38]
Liew CY, Yap CW. QSAR and predictors of eye and skin effects. Mol Inform 2013; 32(3): 281-90.
[http://dx.doi.org/10.1002/minf.201200119] [PMID: 27481523]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy